The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]
NYS Entity Status
NYS Filing Date
NOVEMBER 07, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - GOAL THERAPEUTIC SERVICES, INC.
AROUND THE WEB
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
- Publisher Tronc acquires Daily News, storied NY tabloid
By JENNIFER PELTZ, Associated Press - Monday Sep 4, 2017
NEW YORK (AP) — Newspaper publisher Tronc has acquired the Daily News, a storied New York tabloid newspaper that won a Pulitzer Prize this year but has been buffeted by the changing media environment.Chicago-based Tronc Inc., the publisher of the Los Angeles Times and the Chicago Tribune, announced the deal Monday night, and the Daily News posted a story on its website.Tronc CEO Justin Dearborn said acquiring the paper and its popular website would "provide us with another strategic platform for growing our digital business, expanding our reach and broadening our services for advertisers and marketers," and both Tronc and Daily News executives said the company would maintain the quality of the paper's journalism.
- For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
By Ben Fidler - Wednesday Aug 9, 2017
A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]
- Insurers Battle Families Over Costly Drug for Fatal Disease
By KATIE THOMAS - Thursday Jun 22, 2017
The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]